New
Freenome
The AI engine Fit Assessment
BetaThe company will be attending ViVE 2025 Event
Blurb
Freenome is a biotechnology company with a comprehensive multiomics platform for cancer detection using a routine blood draw.
HQ Location
South San Francisco (United States)
Founded
2014
Employees
501 - 1000
Total funding raised
$1.35B
Last Funding Event
Venture - Series Unknown, $254.00M, February 15, 2024
Smart insights
- Catherine Msc (Chief People Officer) worked at Lilium as Head of People Business Partnering for 1.5 years (2021 - 2022)
- Val Miftakhov (Founder & CEO) worked at Google in various roles, including Head of R&D, Google for Work Incubation, for a total of 4 years (2012 - 2016)
- 6m headcount growth: 25%
- 1Y headcount growth: 94%
- Headcount-to-last-round ratio: 5.3 employees/$M
Freenome is a biotech company developing accurate, accessible, and non-invasive disease screening products for proactively treating cancer and other diseases at their most manageable stages. The company is developing a simple blood test to detect early-stage cancer and make treatments more effective and provides a platform that helps design healthy conditions for an individual based on his/her cell-free genome. The company aims to reinvent disease management through systematized early detection and intervention.